Introduction
============

Prostate cancer (CaP), as the most common genital neoplasm, holds the highest incidence among men in the majority of western countries ([@b1-mmr-16-05-6803]). CaP growth is driven by androgens; therefore, the conventional treatment option is to lower the levels of male sex hormones ([@b2-mmr-16-05-6803]). Current treatment strategies for CaP include surgery, external beam radiotherapy, brachytherapy, chemotherapy and androgen-deprivation therapy (ADT) ([@b2-mmr-16-05-6803],[@b3-mmr-16-05-6803]). ADT often involves surgically removing the testicles or using drugs to block the androgens from affecting the body ([@b4-mmr-16-05-6803]). Unfortunately, ADT has a limited role in preventing majority of patients progressing to castration-resistant prostate cancer (CRPC) and patients with metastatic prostate cancer progress to resistance of ADT ([@b4-mmr-16-05-6803],[@b5-mmr-16-05-6803]). However, previous studies have been unable to identity a mainstay cancer therapy. Thus, the mortality of patients with CRPC continues to be very high ([@b6-mmr-16-05-6803]).

Previous studies have investigated novel molecular therapeutic targets in CRPC and the influence that tumor metastasis has on the biological processes. Activation of the androgen receptor (AR) may stimulate tumor progression and proliferation in prostate cancer ([@b7-mmr-16-05-6803]), Koivisto *et al* ([@b8-mmr-16-05-6803]) determined that the activity of cytochrome P450 (CYP) may increase AR gene amplification and continuous production of testosterone; therefore, the serum androgen levels following castration can still contribute to prostate cancer cell growth and resistance. Seruga *et al* ([@b9-mmr-16-05-6803]) determined that there are three core genes, including human epidermal growth factor receptor 2, transforming growth factor β (TGF-β) and the kinase of SRC family that are able to activate AR transduction pathways without androgen to stimulate. Chaux *et al* ([@b10-mmr-16-05-6803]) suggested that the loss or mutation of tensin homolog have been implicated in unlike properties of aggressive prostate cancer, including increasing the risk of biochemical relapse, reducing the time to metastasis and increasing the death rate in high-risk cohorts of men. However, the molecular mechanisms with oncogenes or tumor suppressors that modulate the levels of critical proteins remain unclear and their relevance in human disease and therapy require further investigation.

In order to provide novel mechanistic insights associated with possible endogenous metastatic pathways in an androgen-deprived environment, the present study used the data from the gene expression profile available provided by Sun *et al* ([@b11-mmr-16-05-6803]) that used the microarray of human prostate cancer xenograft model-LuCaP35 to analyze the gene expression changes between 5 non-castrated and 5 castrated men. The current study identified 201 upregulated differentially expressed genes (DEGs) and 161 downregulated DEGs using a stricter threshold of false discovery rate (FDR)\<0.05 and \|log~2~ fold-change (FC)\|\>1.5. The visual protein-to-protein interaction (PPI) network was constructed using Cytoscape and the modules were identified with the Mcode plugin. The present study used Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway to analyze the potential interactions and functions of DEGs. In conclusion, the present study identified key genes which may have the potential to be biomarkers of tumorigenesis in patients with CRPC.

Materials and methods
=====================

### Microarray data

The transcription profile of GSE33316 was downloaded from the National Center for Biotechnology Information Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo/>) ([@b11-mmr-16-05-6803]). The data used a human prostate cancer xenograft model-LuCaP35, included 5 controlled samples from non-castrated men (GSM823844, GSM823848, GSM823849, GSM823850, GSM823853) and 5 samples from castrated men (GSM823845, GSM823846, GSM823847, GSM823851, GSM823852).

### Differentially expressed gene analysis

The series matrix file was downloaded and a log~2~ transformation was performed. All sample data was normalized using the limma package in R software version 3.3.0 (<https://www.r-project.org/>) ([@b12-mmr-16-05-6803]). The DEGs were obtained with thresholds of \|logFC\|\>1.5 and P\<0.05, using linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Finally, a clustering analysis was performed using the DEGs and a heatmap of different groups including castrated and non-castrated was constructed ([Fig. 1](#f1-mmr-16-05-6803){ref-type="fig"}).

### Construction of PPI network and module analysis

In order to predict protein interactions, which include physical and functional associations the present study used the Search Tool for the Retrieval of Interacting Genes (STRING) to construct the PPI network for DEGs (minimum required interaction score \>0.4) ([@b13-mmr-16-05-6803]). In addition, Cytoscape software version 3.4.0 (<http://cytoscape.org/download_old_versions.html>) was used for visualization of the PPI networks. Following the construction of the PPI network, a module analysis of the network was performed using the Mcode plugin (degree cut-off ≥2 and the nodes with edges ≥2-core) ([@b14-mmr-16-05-6803]). Additionally, the Network Analyzer was used to compute the basic properties of the PPI network, including average clustering coefficient distribution, closeness centrality, average neighborhood connectivity, node degree distribution, shortest path length distribution, and topological coefficients ([@b15-mmr-16-05-6803]).

### GO terms and KEGG pathway analysis

KEGG pathways were investigated by KEGG Orthology Based Annotation System 2.0 online biological tools ([@b16-mmr-16-05-6803]). To analyze the function of DEGs a gene ontology (GO) enrichment analysis was performed using Database for Annotation, Visualization and Integrated Discovery method ([@b17-mmr-16-05-6803]), with a FDR\<0.05 and count \>2 as threshold.

BiNGO, is a useful tool to determine which GO categories are statistically overrepresented in a set of genes or a subgraph of a biological network ([@b18-mmr-16-05-6803]), the present study used the visualization of the results of enriched GO terms and the output the predominant functional themes of a given gene set in the GO hierarchy. The findings are presented in a directed acyclic graph.

Results
=======

### Identification of DEGs

Using microarray expression profiling from GEO database, the present study identified the significant DEGs in castrated samples compared with the non-castrated samples. There were 161 downregulated DEGs and 201 upregulated DEGs, respectively accounting for 44.48 and 55.52% of all DEGs ([Fig. 1](#f1-mmr-16-05-6803){ref-type="fig"}; [Table I](#tI-mmr-16-05-6803){ref-type="table"}). The upregulated genes were more numerous compared with the downregulated genes. A heat map for the expression of the DEGs is presented in [Fig. 1](#f1-mmr-16-05-6803){ref-type="fig"}. The results of hierarchical clustering analysis indicated that the castrated group and non-castrated group were separated by the clustering the of the DEGs, which indicated that the sectionalization was reasonable and the data may be directly used for further analysis.

### Construction of the PPI network using STRING

The STRING database was used to predict the interaction relationship between 362 DEGs (combined score \>0.4). There were 306 nodes and 767 interactions analyzed in the PPI network. The top 30 hub genes are presented in [Fig. 2](#f2-mmr-16-05-6803){ref-type="fig"}, including amyloid β precursor protein (APP), ERBB4, polo like kinase 1 (PLK1), protein kinase C α (PRKCA), actin, alpha 2, smooth muscle, aorta and cyclin A2. The visualization of the PPI network used Cytoscape and is shown in [Fig. 3](#f3-mmr-16-05-6803){ref-type="fig"}.

### Network module analysis

The topology parameter of the PPI network was based on the following six properties: i) Average clustering coefficient distribution; ii) closeness centrality; iii) neighborhood connectivity distribution; iv) node degree distribution; v) shortest path length distribution; and vi) topological coefficients ([Fig. 4](#f4-mmr-16-05-6803){ref-type="fig"}). This analysis revealed that the constructed network is stable and reliable. A total of 10 modules were identified in the PPI network and the top 5 modules were investigated further ([Fig. 5](#f5-mmr-16-05-6803){ref-type="fig"}), which included 23, 14, 12, 9 and 5 genes ([Table II](#tII-mmr-16-05-6803){ref-type="table"}). Additionally, the DEGs in the top 5 modules were enriched in the significant pathways presented in [Table III](#tIII-mmr-16-05-6803){ref-type="table"}. Module A had 23 nodes and 222 interactions. All the DEGs were downregulated in this module. There were 5 enriched KEGG pathways in this module, which involved cyclin B1 (CCNB1) and CCNB2, PLK1 and aurora kinase A (AURKA).

Module B had 14 nodes and 57 interactions. There were 9 upregulated DEGs, including cholinergic receptor muscarinic 2 (CHRM2), sphingosine-1-phosphate receptor 4 (S1PR4), complement component 5a receptor 1 (C5AR1), somatostatin receptor 1 (SSTR1), APP, tachykinin receptor 1 (TACR1), regulator of G protein signaling 2 (RGS2), G protein subunit α 14 and kalirin RhoGEF kinase, and 5 downregulated DEGs, including coagulation factor II thrombin receptor (F2R), free fatty acid receptor 2, cholecystokinin, annexin A1 and neuropeptide Y. For the DEGs in this module, 6 enriched KEGG pathways were identified. The DEGs involved in these pathways were CHRM2, SSTR1, F2R and TACR1.

Module C had 12 nodes and 39 interactions. In this module, the number of upregulated genes was reduced compared with the downregulated genes, 4 and 8, respectively. A total of 6 enriched KEGG pathways were identified, which involved cell division cycle 25, cyclin dependent kinase inhibitor 2A, cyclin E2 and ribonucleotide reductase regulatory subunit M2.

Module D had 9 nodes and 11 interactions. The number of upregulated genes was higher compared with the downregulated genes, 8 and 4, respectively. There were 10 enriched KEGG pathways identified in this module. The DEGs, including Wnt family member 5A (WNT5A) and WNT5B, signal transducer and activator of transcription 6 (STAT6), nuclear factor of activated T-cells 2 and early growth response 2 (EGR2) were screened in these pathways.

Module E had 5 nodes and 10 interactions. It consists of downregulated genes, nudE neurodevelopment protein 1, centromere protein K, zwilch kinetochore protein, centromere protein N and ERCC excision repair 6 like, spindle assembly checkpoint helicase; however, no significantly enriched KEGG pathways were identified in this module.

### Functional analysis

Three types of functions including the biological processes (BP), cellular components (CC) and molecular functions (MF) of DEGs were annotated and classified by a comprehensive GO analysis. The present study identified a total of 26 GO terms based on the DEGs of modules with a FDR\<0.05 and count \>2 as threshold and then these terms were sorted by P-value. From the GO terms, 16 enriched GO terms in BP, 7 enriched GO terms in CC and 3 enriched GO terms enriched in MF were identified ([Fig. 6](#f6-mmr-16-05-6803){ref-type="fig"}; [Table IV](#tIV-mmr-16-05-6803){ref-type="table"}). An acyclic graph was constructed and directed using the BiNGO tool to depict the visual interactions of functions based on the enrichment levels of the GO terms ([Fig. 7](#f7-mmr-16-05-6803){ref-type="fig"}).

Discussion
==========

CaP is the most common non-cutaneous carcinoma among elderly men, and \~180,890 men have been estimated to have been diagnosed in the USA by 2016 ([@b1-mmr-16-05-6803]). ADT as the primary therapeutic strategy for advanced stage of prostate carcinoma has been the conventional treatment since 1942; however, the disease frequently relapses and progresses into CRPC with adaptive responses of androgen receptors ([@b4-mmr-16-05-6803],[@b7-mmr-16-05-6803],[@b19-mmr-16-05-6803]). Therefore, the present study aimed to outline potential prognostic biomarkers or therapeutic targets for CRPC.

In the present study, \~362 DEGs were identified from the gene expression profile analysis. Due to gene-gene interactions it is more accurate to predict the associations of protein functions compared with a single gene and the present study identified 306 interacting genes and constructed a PPI network using the STRING online tool. Accordingly, to show all DEGs, a network of PPI interactions was generated. The DEGs in the PPI network exhibited higher enrichment, indicating a higher degree of modularization; therefore, the present study divided the DEGs into 10 modules for investigating the interactions using Mcode and the top 5 modules were selected for further investigation. Additionally, the GO analysis demonstrated that the function of DEGs in different cluster modules were associated with androgen metabolism and cell cycle. The KEGG pathway analysis was performed to identify the altered pathways in the functional modules. Finally, aldo-keto reductase 3 (AKR1C3), CCNB2, RGS2, nuclear factor of activated T-cells (NFATc2) and PRKCA were significantly enriched in CRPC development.

AKR1C3 is a member of aldo-keto reductase superfamily, which includes \~40 types of proteins and enzymes. These enzymes use NADH or NADPH as cofactors to convert aldehydes and ketones into the relevant alcohols with catalyzed reaction ([@b20-mmr-16-05-6803]). Byrns *et al* ([@b21-mmr-16-05-6803]) showed that AKR1C3 overexpression was associated with the high risk of breast and ovarian cancer. Azzarello *et al* ([@b22-mmr-16-05-6803]) determined that the high expression of AKR1C3 may be a predictor for poor prognosis in patients with renal cell carcinoma, papillary urothelial carcinoma, and Wilms\' tumor. The GO enrichment performed by the present study demonstrated that AKR1C3 was associated with biological processes and molecular functions, such as cellular process, oxidation reduction, steroid dehydrogenase activity and testosterone 17-β-dehydrogenase activity. Therefore, it possible that AKR1C3 is an important enzyme mediated in the progression of CaP into the development of CRPC. Additionally, AKR1C3 is the upregulated DEG in this gene expression profile; therefore, knocking-down the expression of AKR1C3 may lower the androgen sensitivity of CRPC cells.

CCNB2 was identified as the core gene of module A. CCNB2 is a B-type cyclin of the cyclin family. CCNB2 and B1, associated with p34cdc2/cyclin B complex, are essential components of the cell cycle regulatory machinery ([@b23-mmr-16-05-6803]). In the module A, enriched KEGG pathways revealed that CCNB2 was associated with pathways, including cell cycle, FoxO and p53 signaling pathways. In addition, through comparison of functions between GO enrichments and the DEGs, the present study identified that CCNB2, a key enzyme mediating in the progress of oxidation reduction, was associated with the cell cycle. The epithelial-mesenchymal transition (EMT) has a crucial role in the developmental process during which prostate cancer cells acquire migrating and invasive phenotype ([@b11-mmr-16-05-6803],[@b24-mmr-16-05-6803]). Additionally, EMT may promote cancer metastasis and mediate the resistance to ADT in prostate cancer ([@b25-mmr-16-05-6803]). Shiota *et al* ([@b26-mmr-16-05-6803]) identified TGF-β as an EMT inducer that leads AR to acquire castration resistance. A previous study revealed that in the FoxO signaling pathway, CCNB2 may bind TGF-β-RII and may be involved in transforming growth factor b-mediated cell cycle control ([@b27-mmr-16-05-6803]). Therefore, the present study suggested that CCNB2 may be a co-regulator of TGF-β, mediating the development of tumor metastasis and therapeutic resistance; therefore, the effective treatment strategy for CRPC may involve altering the expression of CCNB2. CCNB2 has interactive associations with PLK1 and AURKA in module A, revealing that CCNB2 may also be involved in CRPC by mediating PLK1 and AURKA.

G-protein coupled receptors are important in the physiology of the prostate; therefore, they may be a potential alternative or combinatorial therapeutic targets in the growth processes of tumor cells and AR-mediated signaling pathways ([@b28-mmr-16-05-6803]). The present study identified RGS2 as a differentially expressed gene enriched in the cAMP signaling pathway of module B. In addition, RGS2 has a crucial role in cell cycle according to the GO enrichment analysis. The cell cycle is a succession of events which take place at the cellular level resulting in division and duplication ([@b29-mmr-16-05-6803]) and thus it indicated that RGS2 may associate with the division and metabolism in tumor cells. The expression of RGS2 is upregulated in the castrated samples of the present study, its overexpression may induce a change for the sensitivity of AR. Therefore, a knockdown of the expression of RGS2 may suppress the growth of tumor cells and block the progression from androgen dependence to castration resistance. In module B, RGS2 has interactive associations with CHRM2, SSTR1, F2R, TACR1, C5AR1 and S1PR4, indicating that RGS2 may also be involved in CRPC by mediating these genes.

NFATc2, a member of NFAT family, was identified as a central regulator in activation of gene transcription during immune response ([@b30-mmr-16-05-6803]). However, the present study determined that NFATc2 was a core gene enriched in the Wnt signaling pathway of module D for prostate cancer. NFATc2 may activate in response to the Wnt signaling pathway stimulation and activate β-catenin expression ([@b31-mmr-16-05-6803]). Additionally, β-catenin is a cofactor of AR that may amplify AR signaling to regulate androgen synthesis ([@b32-mmr-16-05-6803]). Therefore, it was hypothesized that NFATc2 may be a key regulator correlated with CRPC. In addition, NFATc2 has interactive associations with EGR2, STAT6, Wnt5A and Wnt5B in module D, revealing that NFATc2 may also be involved in CRPC by mediating these genes.

PRKCA is a member of protein kinase C (PKC) family that may be activated by calcium and the second messenger diacylglycerol ([@b33-mmr-16-05-6803]). Using the PPI network constructed by the present study PRKCA was identified as a hub gene with 11 interactions. Tirado *et al* ([@b34-mmr-16-05-6803]) determined that PRKCA may modulate caveolin-1 to promote resistance to chemotherapy-induced apoptosis in Ewing\'s sarcoma. Lønne *et al* ([@b35-mmr-16-05-6803]) showed that PKCa expression may be a marker for breast cancer aggressiveness. In addition, Lichner *et al* ([@b36-mmr-16-05-6803]) demonstrated that PRKCA may reduce cell proliferation and migration of prostate cancer. However, to the best of our knowledge, there is no experimental study reporting PRKCA to be associated with CRPC. Nonetheless, the PPI network constructed in the present study has indicated that PRKCA may have interactive associations with CRPC, these findings require conformation by future studies.

In summary, based on the gene expression profile analysis in GEO database, the present study identified the DEGs between non-castrated and castrated samples. There were 362 DEGs identified by comprehensive bioinformatics analysis, including AKR1C3, CCNB2, RGS2, NFATc2 and PRKCA, which may have a fundamental role in the development of CRPC and predicted to be involved in the cell cycle pathway. Those findings may be potential biomarkers for the exploration of the biological mechanisms of CRPC and may be used as potential targets for therapeutic intervention or diagnosis of CRPC.

However, the primary limitation of the present study is that as the DEGs remain to be verified by experiments; therefore, further analyses are required to determine the mechanisms in process of malignant progression in CaP. Future studies will aim to use polymerase chain reaction or western blotting to verify expression levels of the key genes in samples between non-castrated and castrated men.

![Hierarchical clustering heat maps of the DEGs. The horizontal axis represents sample names, with GSM823845, GSM823846, GSM823847, GSM823851 and GSM823852 being the castration samples, and GSM823844, GSM823848, GSM823849, GSM823850 and GSM823853 the non-castration samples. The vertical axis indicates the clusters of DEGs: Red color stands for an expression level above the mean and green color stands for the expression lower than the mean. DEGs, differentially expressed genes.](mmr-16-05-6803-g00){#f1-mmr-16-05-6803}

![Top 30 hub genes in from the constructed protein-protein interaction network. The horizontal axis represents degree. The vertical axis indicated hub genes.](mmr-16-05-6803-g01){#f2-mmr-16-05-6803}

![Protein-protein interaction network constructed from the DEGs. Red circles indicate upregulated DEGs and green circles indicate downregulated DEGs. DEGs, differentially expressed genes.](mmr-16-05-6803-g02){#f3-mmr-16-05-6803}

![Topology parameters of protein-protein interaction networks. (A) Average clustering coefficient distribution. (B) Closeness centrality. (C) Neighborhood connectivity distribution. (D) Node-degree distribution. (E) Shortest path length distribution. (F) Topological coefficients.](mmr-16-05-6803-g03){#f4-mmr-16-05-6803}

![Top 5 modules obtained from the protein-protein interaction network of the differentially expressed genes. The circular and triangular nodes represent proteins (triangular nodes indicate hub proteins) and the grey lines represent interactions. Red circles indicate upregulated genes and green circles indicate downregulated genes.](mmr-16-05-6803-g04){#f5-mmr-16-05-6803}

![Biological processes, cellular components and molecular functions of differentially expressed genes were annotated and classified using GO analysis. The horizontal axis indicates the names of GO terms. GO, gene ontology.](mmr-16-05-6803-g05){#f6-mmr-16-05-6803}

![Directed acyclic graph based on the enrichment degree of GO terms. Color depth represents the degree of GO terms enrichment. GO, gene ontology.](mmr-16-05-6803-g06){#f7-mmr-16-05-6803}

###### 

Top 10 upregulated and downregulated genes.

  A, Upregulated                    
  ------------------ -------------- ------------------
  F3                 4.863582313    2.91×10^−3^
  HAGLROS            4.847973534    9.32×10^−6^
  GIMAP7             4.839624566    4.72×10^−3^
  CEL                4.793641494    5.79×10^−4^
  GPAT3              4.585119916    3.68×10^−3^
  FAM3D              4.358475955    2.36×10^−3^
  PDGFRL             3.929026478    1.09×10^−3^
  RGS2               3.899872367    3.01×10^−3^
  UPK3A              3.868345004    5.79×10^−4^
  SI                 3.843651777    7.42×10^−4^
                                    
  B, Downregulated                  
                                    
  Gene symbol        logFC          Adjusted P-value
                                    
  MYBPC1             −4.622857598   7.75×10^−3^
  LAMA1              −4.215584491   1.45×^10−3^
  S100P              −4.16482084    9.77×10^−3^
  LEFTY1             −4.151682649   8.22×10^−3^
  DEFB1              −3.863896718   1.59×10^−3^
  LOX                −3.400271316   1.06×10^−3^
  DHRS2              −3.381711553   2.59×10^−3^
  CCK                −3.328128227   1.53×10^−3^
  KRT19              −3.323100902   6.53×10^−3^
  ANGPYL4            −3.29177361    9.74×10^−3^

FC, fold-change.

###### 

The modules of networks.

  Module name   Nodes   Edges   Cluster scores
  ------------- ------- ------- ----------------
  A             23      222     20.182
  B             14        57    8.769
  C             12        39    7.091
  D               9       11    5.75
  E               5       10    5.00

###### 

KEGG pathways of the modules in the present study.

  A, Module A                                                                                                   
  -------------------------------------------------------------------- ---------------------------------------- -------------
  hsa04114: Oocyte meiosis                                             CCNB2, CCNB1, PLK1, AURKA                1.59×10^−6^
  hsa04914: Progesterone-mediated oocyte maturation                    CCNB2, CCNB1, PLK1                       4.49×10^−5^
  hsa04110: Cell cycle                                                 CCNB2, CCNB1, PLK1                       8.87×10^−5^
  hsa04068: FoxO signaling pathway                                     CCNB2, CCNB1, PLK1                       1.11×10^−4^
  hsa04115: p53 signaling pathway                                      CCNB2, CCNB1                             1.10×10^−3^
                                                                                                                
  B, Module B                                                                                                   
                                                                                                                
  KEGG pathways                                                        Genes                                    P-value
                                                                                                                
  hsa04080: Neuroactive ligand-receptor interaction                    CHRM2, SSTR1, F2R, TACR1, C5AR1, S1PR4   5.31×10^−6^
  hsa04024: cAMP signaling pathway                                     CHRM2, SSTR1, NPY, RGS2, FFAR2           1.70×10^−5^
  hsa04020: Calcium signaling pathway                                  GNA14, CHRM2, TACR1, F2R                 2.02×10^−4^
  hsa04610: Complement and coagulation cascades                        C5AR1, F2R                               7.29×10^−3^
  hsa04810: Regulation of actin cytoskeleton                           CHRM2, F2R                               4.61×10^−3^
  hsa04151: PI3K-Akt signaling pathway                                 CHRM2, F2R                               1.03×10^−2^
                                                                                                                
  C, Module C                                                                                                   
                                                                                                                
  KEGG pathways                                                        Genes                                    P-value
                                                                                                                
  hsa04115: p53 signaling pathway                                      RRM2, CCNG2, CDKN2A, CCNE2               5.94×10^−6^
  hsa04110: Cell cycle                                                 CDC25B, CDKN2A, CDC25A, CCNE2            5.46×10^−5^
  hsa05206: MicroRNAs in cancer                                        CDC25B, CDKN2A, CDC25A, CCNE2            1.44×10^−3^
  hsa04914: Progesterone-mediated oocyte maturation                    CDC25A, CDC25B                           1.14×10^−2^
  hsa04068: FoxO signaling pathway                                     PLK2, CCNG2                              2.05×10^−2^
  hsa05203: Viral carcinogenesis                                       CDKN2A, CCNE2                            4.42×10^−2^
                                                                                                                
  D, Module D                                                                                                   
                                                                                                                
  KEGG pathways                                                        Genes                                    P-value
                                                                                                                
  hsa05166: HTLV-I infection                                           EGR2, WNT5A, WNT5B, NFATC2               1.11×10^−3^
  hsa04310: Wnt signaling pathway                                      WNT5A, WNT5B, NFATC2                     2.08×10^−3^
  hsa05161: Hepatitis B                                                EGR2, STAT6, NFATC2                      2.20×10^−3^
  hsa04360: Axon guidance                                              WNT5A, WNT5B, NFATC2                     3.70×10^−3^
  hsa05217: Basal cell carcinoma                                       WNT5A, WNT5B                             4.41×10^−3^
  hsa04916: Melanogenesis                                              WNT5A, WNT5B                             1.36×10^−2^
  hsa04550: Signaling pathways regulating pluripotency of stem cells   WNT5A, WNT5B                             2.59×10^−2^
  hsa04390: Hippo signaling pathway                                    WNT5A, WNT5B                             3.00×10^−2^
  hsa04150: mTOR signaling pathway                                     WNT5A, WNT5B                             3.01×10^−2^
  hsa05205: Proteoglycans in cancer                                    WNT5A, WNT5B                             5.00×10^−2^

KEGG, Kyoto Encyclopedia of Genes and Genomes.

###### 

Enriched GO functions for the DEGs.

  A, Biological processes                                                                       
  ------------------------- --------------------------------------------- ------- ------------- -----------------------------------------
  GO:0000280                Nuclear division                              31      3.83×10^−6^   CCNB1, CCNB2, PLK1, AURKB, CCNG2
  GO:0007067                Mitosis                                       31      3.97×10^−6^   KIF23, CCNA2, CCNB2, PLK1, CDCA2
  GO:0000087                M phase of mitotic cell cycle                 31      5.90×10^−6^   KIF23, KIFC1, KIF22, NEK2, HAUS1
  GO:0000278                Mitotic cell cycle                            41      8.90×10^−6^   CDKN1A, CCNB2, PLK2, PLK1, RNF2
  GO:0048285                Organelle fission                             31      9.98×10^−6^   NDC80, UBE2C, CDC25A, CCNB1, CCNB2
  GO:0022403                Cell cycle phase                              42      7.08×10^−5^   BCAT1, KIF23, KIF22, KIFC1, PRC1
  GO:0051301                Cell division                                 34      9.05×10^−5^   CCNE2, SPC25, NDE1, CDKN2A, NCAPG
  GO:0000279                M phase                                       36      1.25×10^−4^   CCNA2, ERCC6L, KIF11, DLGAP5, NUF2
  GO:0007049                Cell cycle                                    61      4.66×10^−4^   CCNB2, PLK2, RGS2, MAPK13, PLK1
  GO:0022402                Cell cycle process                            48      1.36×10^−3^   BCAT1, KIF23, KIF22, KIFC1, PRC1
  GO:0009101                Glycoprotein biosynthetic process             22      1.56×10^−3^   GALNT3, ST6GAL1, ST6GAL2, LDLR, FUT8
  GO:0009100                Glycoprotein metabolic process                24      7.23×10^−3^   GALNT3, ST6GAL1, ST8SIA1, CHST3, ABCG1
  GO:0043413                Biopolymer glycosylation                      18      1.72×10^−2^   GALNT3, ST6GAL1, ABCG1, MPDU1, B3GNT3
  GO:0006486                Protein amino acid glycosylation              18      1.73×10^−2^   COG7, ST3GAL4, B3GNT7, ST3GAL6, MPDU1
  GO:0070085                Glycosylation                                 18      1.73×10^−2^   GALNT3, ST6GAL1, ST6GAL2, ALG1, ST3GAL1
  GO:0055114                Oxidation reduction                           23      3.15×10^−2^     DHRS9, ACADL, GMPR, ALDH1A1, AKR1C3
                                                                                                
  B, Cellular components                                                                        
                                                                                                
  Term                      Function                                      Count   FDR           Examples of DEGs
                                                                                                
  GO:0005819                Spindle                                       20      5.53×10^−3^   KIF23, NDE1, APP, PLK1, SKA1
  GO:0000779                Condensed chromosome, centromeric region      13      1.02×10^−2^   CENPN, NUF2, CENPF, NDC80, AURKB
  GO:0000793                Condensed chromosome                          18      1.36×10^−2^   CENPN, NEK2, SKA1, CENPF, CHEK1,
  GO:0000777                Condensed chromosome kinetochore              12      1.61×10^−2^   SPC25, CENPN, NDE1, CENPA, NUF2,
  GO:0005624                Membrane fraction                             56      4.37×10^−2^   NPR3, RGS16, CCNB2, APP, CHRM2
  GO:0000776                Kinetochore                                   13      4.48×10^−2^   KIF22, CENPN, NUF2, CENPF, CENPK
  GO:0005626                Insoluble fraction                            56      4.12×10^−2^   CYP2J2, CADM1, CCNB2, NPR3, RGS16
                                                                                                
  C, Molecular functions                                                                        
                                                                                                
  Term                      Function                                      Count   FDR           Examples of DEGs
                                                                                                
  GO:0008373                Sialyltransferase activity                    7       4.14×10^−2^   ST6GAL1, ST6GAL2, ST3GAL4, ST3GAL6
  GO:0016229                Steroid dehydrogenase activity                4       1.89×10^−2^   AKR1C3, HSD11B2, DHRS9, HSD17B6
  GO:0050327                Testosterone 17-beta-dehydrogenase activity   2       2.62×10^−2^   AKR1C3, HSD17B6

GO, gene ontology; FDR, false discovery rate; DEGs, differentially expressed genes.
